middle.news
How Clinuvel’s Ninth Year of Growth Fuels Its Vitiligo Clinical Ambitions
2:31am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Clinuvel’s Ninth Year of Growth Fuels Its Vitiligo Clinical Ambitions
2:31am on Saturday 30th of August, 2025 AEST
Key Points
Revenues up 10% to AUD 105.3 million
Net profit after tax increased 2% to AUD 36.2 million
Expenses rose 20% due to vitiligo clinical program and expanded operations
Cash reserves grew 22% to AUD 224.1 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE